Intravitreal bevacizumab [avastin] injection for neovascular glaucoma

ABSTRACT

To report two cases with neovascular glaucoma secondary to ischemic central retinal vein occlusion [CRVO] who were treated with intravitreal bevacizumab. Two patients were referred for neovascular glaucoma following CRVO. Visual acuity was light perception. Both eyes had extensive iris neovascularization [NVI], synechial angle closure and high intraocular pressure [IOP] in spite of anti-glaucoma medications. After obtaining informed consent both eye received an intravitreal injection of 2.5 mg [0.1 ml] bevacizumab [Avastin]. Both eyes demonstrated dramatic IOP reduction together with decreased severity and extent of NVI during 4 weeks of follow up. Visual acuity remained unchanged. Despite the dramatic short-term response in terms of IOP reduction and regression of neovascularization, due to limited clinical experience, one should consider this novel indication for bevacizumab cautiously